DiaMedica Therapeutics (DMAC) Cash from Investing Activities (2018 - 2026)

DiaMedica Therapeutics has reported Cash from Investing Activities for 9 years, with the latest figure at -$2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 131.92% year-over-year to -$2.1 million; the trailing twelve-month figure through Mar 2026 stood at -$10.9 million (down 199.54% YoY), and the FY2025 full-year result was -$2.2 million, down 125.6% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$2.1 million, down from $8.0 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $9.0 million in Q2 2025, with the low at -$28.1 million in Q2 2023.
• Historically, Cash from Investing Activities has averaged -$147235.3 across 5 years, with a median of $2.5 million in 2022.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities surged 24700.0% — and 2023, when it sank 1212.66%.
• DiaMedica Therapeutics' Cash from Investing Activities stood at $4.7 million in 2022, then climbed by 29.64% to $6.1 million in 2023, then slipped by 15.01% to $5.2 million in 2024, then jumped by 53.6% to $8.0 million in 2025, then plunged by 126.44% to -$2.1 million in 2026.
• The last three Cash from Investing Activities figures came in at -$2.1 million (Q1 2026), $8.0 million (Q4 2025), and -$25.8 million (Q3 2025), per Business Quant data.